Clinical Trials Directory

Trials / Completed

CompletedNCT01299012

Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus

Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus, a Retrospective Chart Review

Status
Completed
Phase
Study type
Observational
Enrollment
30 (actual)
Sponsor
University at Buffalo · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Evaluating the use of Liraglutide in patients with Type 1 Diabetes.

Detailed description

This investigation will be a retrospective chart review of in type 1 diabetics who have been treated with liraglutide. The study will be conducted at Diabetes-Endocrinology Center of WNY at Millard Fillmore Hospital, affiliated to the State University of New York at Buffalo. Study Population: 40 patients with type 1 diabetes on treatment with either continuous subcutaneous insulin infusion (CSII; also known as insulin pump) or multiple (four or more) injections of insulin per day on continuous glucose monitoring system (CGMS) will be included in the study. These patients with type 1 diabetes have been treated with liraglutide in addition to insulin. The investigators would retrospectively review their charts to evaluate decreases in fasting, postprandial and the overall mean glucose concentrations. The investigators will compare the mean fasting, the mean weekly glucose and the standard deviation of weekly blood glucose concentrations as recorded by continuous glucose monitoring prior to and following one week and 12 weeks of treatment with liraglutide daily. In addition, the investigators will compare the time spent at glucose concentrations \>150 and 200mg/dl and \<70 and \<40 mg/dl. HbA1c levels before and after 12 weeks of treatment with liraglutide daily will be compared.

Conditions

Interventions

TypeNameDescription
DRUGLiraglutideLiraglutide s/c 0.6mg once daily.

Timeline

Start date
2010-10-01
Primary completion
2013-02-01
Completion
2013-06-01
First posted
2011-02-18
Last updated
2017-02-09

Source: ClinicalTrials.gov record NCT01299012. Inclusion in this directory is not an endorsement.